Amplatzer™Amulet™ Post-Market Study (Amulet™PMS)

NCT ID: NCT02447081

Last Updated: 2019-12-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1088 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-06-01

Study Completion Date

2018-10-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This was a prospective, multicenter, observational, nonrandomized study to compile real world outcome data on the use of the Amulet™ device in non-valvular atrial fibrillation (NVAF) subjects. The study was designed to follow the Instructions For Use (IFU) to gather data on the implant procedure through two years of follow up with the Amulet™ device in a commercial clinical setting."

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of 1088 subjects were enrolled in the study at 61 sites internationally, outside the United States.

The study assessed acute and late serious adverse events and reports the rate of stroke and bleeding events through 2 years. No formal hypothesis were tested for this observational post-market study.

Each patient was followed at study visits at baseline, implant, 1-3 months, 6 months, 12 months, and 24 months post implant."

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Thromboembolism Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects implanted with Amulet Device

All subjects who receive the Amulet device will be followed.

Subjects implanted with Amulet Device

Intervention Type DEVICE

Percutaneous Left Atrial Appendage occlusion with successful implant of occlusion device.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Subjects implanted with Amulet Device

Percutaneous Left Atrial Appendage occlusion with successful implant of occlusion device.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject with history of paroxysmal, persistent or permanent NVAF
2. Subject who is 18 years or older, or of legal age to give informed consent specific to state and national law
3. Subject who is eligible for an Amulet LAA Occluder device according to current international guidelines and per physician discretion
4. Subject who is willing and capable of providing informed consent, participating in all associated study activities

Exclusion Criteria

1. Subject with evidence of an intracardiac thrombus
2. Subject with active infection or active endocarditis or other infections producing bacteremia
3. Subject where the placement of the device would interfere with any intracardiac or intravascular structures
4. Subject with any medical disorder that would interfere with completion or evaluation of clinical study results
5. Women of childbearing potential who are, or plan to become, pregnant during the time of the study (method of assessment per physician discretion)
6. Subject with LAA anatomy that does not accommodate a device per the sizing guidelines
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott Medical Devices

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David Hildick-Smith, MD

Role: PRINCIPAL_INVESTIGATOR

Brighton and Sussex University Hospitals

Claudio Tondo, MD PhD

Role: PRINCIPAL_INVESTIGATOR

University of Milan

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fiona Stanley Hospital

Murdoch, Western Australia, Australia

Site Status

Universitaire Ziekenhuizen Gasthuisberg

Leuven, , Belgium

Site Status

Hospital Clinico San Borja Arriaran

Santiago, , Chile

Site Status

Rigshospitalet

Copenhagen, , Denmark

Site Status

Helsinki University Central Hospital

Helsinki, Uusimaa, Finland

Site Status

Turku University Hospital

Turku, , Finland

Site Status

Hopital Haut Leveque

Pessac, Aquitaine, France

Site Status

CHU du Bocage

Dijon, Burgundy, France

Site Status

CHRU Lille

Lille, North-Calais, France

Site Status

CHU d'Amiens

Amiens, Picardy, France

Site Status

Klinikum Coburg

Coburg, Bavaria, Germany

Site Status

Internistische Klinik Dr. Müller, München-Thalkirchen

Munich, Bavaria, Germany

Site Status

Universitaetsklinikum Ulm

Ulm, Bavaria, Germany

Site Status

Zentrum fur Herzgesundheit/Kardiologie am Alice Hospital Darmstadt

Darmstadt, Hesse, Germany

Site Status

CardioVaskuläres Centrum St. Katharinen

Frankfurt am Main, Hesse, Germany

Site Status

Universitätsklinikum Düsseldorf

Düsseldorf, North Rhine-Westphal, Germany

Site Status

Zentralklinik Bad Berka Gmbh

Bad Berka, Thuringia, Germany

Site Status

Zentralklinik Bad Berka

Bad Berka, , Germany

Site Status

Segeberger Kliniken Gmbh

Bad Segeberg, , Germany

Site Status

Segeberger Kliniken GmbH

Bad Segeberg, , Germany

Site Status

Charité - Universitätsmedizin Berlin (CBF)

Berlin, , Germany

Site Status

St. Marien Hospital Bonn

Bonn, , Germany

Site Status

Herzzentrum Dresden

Dresden, , Germany

Site Status

Cardioangiologisches Centrum Bethanien

Frankfurt, , Germany

Site Status

Klinikum Frankfurt Höchst

Frankfurt, , Germany

Site Status

Harzklinikum Dorothea Christiane Erxleben GmbH

Quedlinburg, , Germany

Site Status

Rems-Murr-Klinikum Winnenden

Winnenden, , Germany

Site Status

Mater Hospital

Dublin, , Ireland

Site Status

The Chaim Sheba Medical Center

Tel Litwinsky, , Israel

Site Status

Nuovo Ospedale Civile Sant'Agostino Estense

Baggiovara, Modena, Italy

Site Status

Ospedale dell'Angelo and Ospedale SS Giovanni e Paolo Venezia

Mestre, Veneto, Italy

Site Status

Università degli Studi di Padova

Padua, Veneto, Italy

Site Status

Azienda Ospedaliera S. Anna e S. Sebastiano

Caserta, , Italy

Site Status

Ospedale del Cuoro Fondazione C. N. R. Regione Toscana G. Monasterio

Massa, , Italy

Site Status

Cardiac Arrhythmia Research Center, Centro Cardiologico Monzino, Unveristiy of Milan

Milan, , Italy

Site Status

San Raffaele Hospital

Milan, , Italy

Site Status

Ospedale Luigi Sacco

Milan, , Italy

Site Status

Amsterdam Academic Medical Centre

Veenendaal, , Netherlands

Site Status

Ulleval Universitetssykehus

Oslo, , Norway

Site Status

Slaskie Centrum Chorob Serca

Warsaw, , Poland

Site Status

The Cardinal Stefan Wyszynski Institute of Cardiology

Warsaw, , Poland

Site Status

Hospital Universitario Virgen Macarena

Seville, Andalusia, Spain

Site Status

Hospital Universitario Son Espases

Palma de Mallorca, Balearic Island, Spain

Site Status

Hospital Universitario de Salamanca

Salamanca, Castille and León, Spain

Site Status

Hospital de la Santa Creu I Sant Pau

Barcelona, Catalonia, Spain

Site Status

Hospital Universitario Infanta Cristina

Badajoz, Extremadura, Spain

Site Status

Hospital Clinic I Provincial de Barcelona

Barcelona, , Spain

Site Status

Karolinska University Hospital Huddinge

Stockholm, , Sweden

Site Status

Liverpool Heart and Chest Hospital

Liverpool, Northwest England, United Kingdom

Site Status

The Royal Sussex Country Hospital

Brighton, South East England, United Kingdom

Site Status

St Thomas Hospital

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia Belgium Chile Denmark Finland France Germany Ireland Israel Italy Netherlands Norway Poland Spain Sweden United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

De Caterina AR, Nielsen-Kudsk JE, Schmidt B, Mazzone P, Fischer S, Lund J, Montorfano M, Gage R, Lam SCC, Berti S. Gender difference in left atrial appendage occlusion outcomes: Results from the Amplatzer Amulet Observational Study. Int J Cardiol Heart Vasc. 2021 Jul 26;35:100848. doi: 10.1016/j.ijcha.2021.100848. eCollection 2021 Aug.

Reference Type DERIVED
PMID: 34381870 (View on PubMed)

Piayda K, Hellhammer K, Nielsen-Kudsk JE, Schmidt B, Mazzone P, Berti S, Fischer S, Lund J, Montorfano M, Della Bella P, Gage R, Zeus T. Clinical outcomes of patients undergoing percutaneous left atrial appendage occlusion in general anaesthesia or conscious sedation: data from the prospective global Amplatzer Amulet Occluder Observational Study. BMJ Open. 2021 Mar 24;11(3):e040455. doi: 10.1136/bmjopen-2020-040455.

Reference Type DERIVED
PMID: 33762228 (View on PubMed)

Aminian A, De Backer O, Nielsen-Kudsk JE, Mazzone P, Berti S, Fischer S, Lund J, Montorfano M, Lam SCC, Freixa X, Gage R, Diener HC, Schmidt B. Incidence and clinical impact of major bleeding following left atrial appendage occlusion: insights from the Amplatzer Amulet Observational Post-Market Study. EuroIntervention. 2021 Oct 20;17(9):774-782. doi: 10.4244/EIJ-D-20-01309.

Reference Type DERIVED
PMID: 33495144 (View on PubMed)

Tarantini G, D'Amico G, Schmidt B, Mazzone P, Berti S, Fischer S, Lund J, Montorfano M, Della Bella P, Lam SCC, Cruz-Gonzalez I, Gage R, Zhao H, Omran H, Odenstedt J, Nielsen-Kudsk JE. The Impact of CHA2DS2-VASc and HAS-BLED Scores on Clinical Outcomes in the Amplatzer Amulet Study. JACC Cardiovasc Interv. 2020 Sep 28;13(18):2099-2108. doi: 10.1016/j.jcin.2020.06.003.

Reference Type DERIVED
PMID: 32972570 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SJM-CIP-10053

Identifier Type: -

Identifier Source: org_study_id